{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:28:55Z","timestamp":1793831335559,"version":"4.6.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40265-023-01862-z","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T15:26:18Z","timestamp":1680708378000},"page":"577-585","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?"],"prefix":"10.1007","volume":"83","author":[{"given":"Ayedh K.","family":"Alamri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy L.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"issue":"1","key":"1862_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ccl.2021.08.007","volume":"40","author":"AK Alamri","year":"2022","unstructured":"Alamri AK, Ma CL, Ryan JJ. Left heart disease-related pulmonary hypertension. Cardiol Clin. 2022;40(1):69\u201376.","journal-title":"Cardiol Clin"},{"issue":"1","key":"1862_CR2","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","volume":"53","author":"G Simonneau","year":"2019","unstructured":"Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913.","journal-title":"Eur Respir J"},{"issue":"1","key":"1862_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/bph.15016","volume":"178","author":"N Sommer","year":"2021","unstructured":"Sommer N, Ghofrani HA, Pak O, Bonnet S, Provencher S, Sitbon O, et al. Current and future treatments of pulmonary arterial hypertension. Br J Pharmacol. 2021;178(1):6\u201330.","journal-title":"Br J Pharmacol"},{"issue":"9","key":"1862_CR4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.healun.2017.02.016","volume":"36","author":"H Gall","year":"2017","unstructured":"Gall H, Felix JF, Schneck FK, Milger K, Sommer N, Voswinckel R, et al. The Giessen Pulmonary Hypertension Registry: survival in pulmonary hypertension subgroups. J Heart Lung Transplant. 2017;36(9):957\u201367.","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"1862_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/diseases6020038","volume":"6","author":"NS Lan","year":"2018","unstructured":"Lan NS, Massam BD, Kulkarni SS, Lang CC. Pulmonary arterial hypertension: pathophysiology and treatment. Diseases. 2018;6(2):38.","journal-title":"Diseases"},{"issue":"24","key":"1862_CR6","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1136\/heartjnl-2012-301992","volume":"98","author":"G Strange","year":"2012","unstructured":"Strange G, Playford D, Stewart S, Deague JA, Nelson H, Kent A, et al. Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart. 2012;98(24):1805\u201311.","journal-title":"Heart"},{"issue":"5","key":"1862_CR7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/MCP.0000000000000510","volume":"24","author":"J Weatherald","year":"2018","unstructured":"Weatherald J, Boucly A, Sitbon O. Risk stratification in pulmonary arterial hypertension. Curr Opin Pulm Med. 2018;24(5):407\u201315.","journal-title":"Curr Opin Pulm Med"},{"issue":"2","key":"1862_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1161\/01.CIR.0000102381.57477.50","volume":"109","author":"R Budhiraja","year":"2004","unstructured":"Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation. 2004;109(2):159\u201365.","journal-title":"Circulation"},{"issue":"25S","key":"1862_CR9","doi-asserted-by":"publisher","first-page":"D4","DOI":"10.1016\/j.jacc.2013.10.025","volume":"62","author":"RM Tuder","year":"2013","unstructured":"Tuder RM, Archer SL, Dorfm\u00fcller P, Erzurum SC, Guignabert C, Michelakis E, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25S):D4\u201312.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1862_CR10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1056\/NEJM199507273330403","volume":"333","author":"A Giaid","year":"1995","unstructured":"Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333(4):214\u201321.","journal-title":"N Engl J Med"},{"issue":"7","key":"1862_CR11","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1172\/JCI33338","volume":"119","author":"Y-Y Zhao","year":"2009","unstructured":"Zhao Y-Y, Zhao YD, Mirza MK, Huang JH, Potula H-HS, Vogel SM, et al. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J Clin Investig. 2009;119(7):2009\u201318.","journal-title":"J Clin Investig"},{"issue":"2","key":"1862_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1056\/NEJM199207093270202","volume":"327","author":"BW Christman","year":"1992","unstructured":"Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327(2):70\u20135.","journal-title":"N Engl J Med"},{"issue":"9","key":"1862_CR13","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1016\/j.freeradbiomed.2012.02.041","volume":"52","author":"DM Tabima","year":"2012","unstructured":"Tabima DM, Frizzell S, Gladwin MT. Reactive oxygen and nitrogen species in pulmonary hypertension. Free Radic Biol Med. 2012;52(9):1970\u201386.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"1862_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Gali\u00e8","year":"2016","unstructured":"Gali\u00e8 N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67\u2013119.","journal-title":"Eur Heart J"},{"issue":"38","key":"1862_CR15","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RM, Brida M, et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur Heart J. 2022;43(38):3618\u2013731.","journal-title":"Eur Heart J"},{"issue":"2","key":"1862_CR16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.14797\/CBHS2234","volume":"17","author":"KN Qaiser","year":"2021","unstructured":"Qaiser KN, Tonelli AR. Novel treatment pathways in pulmonary arterial hypertension. Methodist Debakey Cardiovasc J. 2021;17(2):106.","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"22","key":"1862_CR17","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","volume":"119","author":"N Gali\u00e8","year":"2009","unstructured":"Gali\u00e8 N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894\u2013903.","journal-title":"Circulation"},{"issue":"20","key":"1862_CR18","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1056\/NEJMoa050010","volume":"353","author":"N Gali\u00e8","year":"2005","unstructured":"Gali\u00e8 N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"1862_CR19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1209657","volume":"369","author":"H-A Ghofrani","year":"2013","unstructured":"Ghofrani H-A, D\u2019Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319\u201329.","journal-title":"N Engl J Med"},{"issue":"3","key":"1862_CR20","doi-asserted-by":"publisher","first-page":"1602425","DOI":"10.1183\/13993003.02425-2016","volume":"50","author":"MM Hoeper","year":"2017","unstructured":"Hoeper MM, Simonneau G, Corris PA, Ghofrani H-A, Klinger JR, Langleben D, et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J. 2017;50(3):1602425.","journal-title":"Eur Respir J"},{"issue":"9288","key":"1862_CR21","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","volume":"358","author":"RN Channick","year":"2001","unstructured":"Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. Lancet. 2001;358(9288):1119\u201323.","journal-title":"Lancet"},{"issue":"9630","key":"1862_CR22","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","volume":"371","author":"N Gali\u00e8","year":"2008","unstructured":"Gali\u00e8 N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093\u2013100.","journal-title":"Lancet"},{"issue":"23","key":"1862_CR23","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","volume":"117","author":"N Gali\u00e8","year":"2008","unstructured":"Gali\u00e8 N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010\u20139.","journal-title":"Circulation"},{"key":"1862_CR24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick RN, Delcroix M, Gali\u00e8 N, Ghofrani H-A, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809\u201318.","journal-title":"N Engl J Med"},{"issue":"5","key":"1862_CR25","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","volume":"127","author":"Z-C Jing","year":"2013","unstructured":"Jing Z-C, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013;127(5):624\u201333.","journal-title":"Circulation"},{"issue":"6","key":"1862_CR26","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1378\/chest.11-2212","volume":"142","author":"VF Tapson","year":"2012","unstructured":"Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012;142(6):1383\u201390.","journal-title":"Chest"},{"issue":"6","key":"1862_CR27","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1164\/rccm.201908-1640OC","volume":"201","author":"RJ White","year":"2020","unstructured":"White RJ, Jerjes-Sanchez C, Bohns Meyer GM, Pulido T, Sepulveda P, Wang KY, et al. Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial. Am J Respir Crit Care Med. 2020;201(6):707\u201317.","journal-title":"Am J Respir Crit Care Med"},{"issue":"26","key":"1862_CR28","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","volume":"373","author":"O Sitbon","year":"2015","unstructured":"Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Gali\u00e8 N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522\u201333.","journal-title":"N Engl J Med"},{"issue":"146","key":"1862_CR29","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0093-2017","volume":"26","author":"AR Hemnes","year":"2017","unstructured":"Hemnes AR, Humbert M. Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled. Eur Respir Rev. 2017;26(146): 170093.","journal-title":"Eur Respir Rev"},{"issue":"16","key":"1862_CR30","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1007\/s00018-017-2510-4","volume":"74","author":"M Orriols","year":"2017","unstructured":"Orriols M, Gomez-Puerto MC, Ten Dijke P. BMP type II receptor as a therapeutic target in pulmonary arterial hypertension. Cell Mol Life Sci. 2017;74(16):2979\u201395.","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"1862_CR31","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1136\/jim-2021-002027","volume":"69","author":"H Deshwal","year":"2021","unstructured":"Deshwal H, Weinstein T, Sulica R. Advances in the management of pulmonary arterial hypertension. J Investig Med. 2021;69(7):1270\u201380.","journal-title":"J Investig Med"},{"issue":"13","key":"1862_CR32","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","volume":"384","author":"M Humbert","year":"2021","unstructured":"Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med. 2021;384(13):1204\u201315.","journal-title":"N Engl J Med"},{"key":"1862_CR33","unstructured":"MERCK. Merck announces positive top-line results from pivotal phase 3 STELLAR trial evaluating sotatercept for the treatment of adults with pulmonary arterial hypertension (PAH). Merck; 2022."},{"key":"1862_CR34","doi-asserted-by":"publisher","unstructured":"Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2213558. Epub 6 Mar 2023.","DOI":"10.1056\/NEJMoa2213558"},{"issue":"24","key":"1862_CR35","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1161\/CIRCULATIONAHA.114.006974","volume":"130","author":"M Humbert","year":"2014","unstructured":"Humbert M, Lau EM, Montani D, Ja\u00efs X, Sitbon O, Simonneau G. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2014;130(24):2189\u2013208.","journal-title":"Circulation"},{"issue":"1","key":"1862_CR36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1164\/rccm.200707-1037OC","volume":"178","author":"F Perros","year":"2008","unstructured":"Perros F, Montani D, Dorfm\u00fcller P, Durand-Gasselin I, Tcherakian C, Le Pavec J, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;178(1):81\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"1862_CR37","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1164\/rccm.201001-0123OC","volume":"182","author":"HA Ghofrani","year":"2010","unstructured":"Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010;182(9):1171\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"1862_CR38","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","volume":"127","author":"MM Hoeper","year":"2013","unstructured":"Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Gali\u00e9 N, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013;127(10):1128\u201338.","journal-title":"Circulation"},{"key":"1862_CR39","unstructured":"Tenax Therapeutics. Clinical development. The Impres Trial of imatinib as a treatment of PAH. WHO Group 1: pulmonary arterial hypertension (PAH). 2023."},{"issue":"6","key":"1862_CR40","doi-asserted-by":"publisher","first-page":"2102356","DOI":"10.1183\/13993003.02356-2021","volume":"60","author":"A Galkin","year":"2022","unstructured":"Galkin A, Sitapara R, Clemons B, Garcia E, Kennedy M, Guimond D, et al. Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension. Eur Respir J. 2022;60(6):2102356.","journal-title":"Eur Respir J"},{"key":"1862_CR41","doi-asserted-by":"crossref","unstructured":"McLaughlin V, Channick R, Walsh B, Keating M, Gilder K, Cabell C, et al. Study design of the phase 3 advance program evaluating time-to-clinical events and exercise capacity in patients with pulmonary arterial hypertension treated with ralinepag. In: C51 closer to the heart: update on approved therapies for PAH. American Thoracic Society; 2019. p. A5074-A.","DOI":"10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A5074"},{"issue":"4","key":"1862_CR42","doi-asserted-by":"publisher","first-page":"1901030","DOI":"10.1183\/13993003.01030-2019","volume":"54","author":"F Torres","year":"2019","unstructured":"Torres F, Farber H, Ristic A, McLaughlin V, Adams J, Zhang J, et al. Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. Eur Respir J. 2019;54(4):1901030.","journal-title":"Eur Respir J"},{"issue":"4","key":"1862_CR43","doi-asserted-by":"publisher","first-page":"353","DOI":"10.4070\/kcj.2018.0281","volume":"49","author":"S-A Chang","year":"2019","unstructured":"Chang S-A, Kim H-K, Chang HJ, Kim D-K. Acute hemodynamic changes after single administration of udenafil in pulmonary arterial hypertension: a phase IIa study. Korean Circ J. 2019;49(4):353\u201360.","journal-title":"Korean Circ J."},{"issue":"8","key":"1862_CR44","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.clinthera.2019.05.006","volume":"41","author":"H-J Chang","year":"2019","unstructured":"Chang H-J, Song S, Chang S-A, Kim H-K, Jung H-O, Choi J-H, et al. Efficacy and safety of udenafil for the treatment of pulmonary arterial hypertension: a placebo-controlled, double-blind, phase IIb clinical trial. Clin Ther. 2019;41(8):1499\u2013507.","journal-title":"Clin Ther"},{"issue":"2","key":"1862_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12088","volume":"12","author":"HM Lazarus","year":"2022","unstructured":"Lazarus HM, Denning J, Wring S, Palacios M, Hoffman S, Crizer K, et al. A trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (ELEVATE 2). Pulm Circ. 2022;12(2): e12088.","journal-title":"Pulm Circ."},{"issue":"Suppl 2","key":"1862_CR46","doi-asserted-by":"publisher","first-page":"ehac544.1929","DOI":"10.1093\/eurheartj\/ehac544.1929","volume":"43","author":"V McLaughlin","year":"2022","unstructured":"McLaughlin V, Hoeper M, Tamura Y, Backer A, Boyanova N, Kracker H, et al. UNISUS study design: a phase 3 superiority study comparing the efficacy, safety, and tolerability of macitentan 75 mg vs macitentan 10 mg in patients with pulmonary arterial hypertension (PAH). Eur Heart J. 2022;43(Suppl 2):ehac544.1929.","journal-title":"Eur Heart J"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01862-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01862-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01862-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:14:40Z","timestamp":1744715680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01862-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1862"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01862-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"16 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"John J. Ryan, and his research, is supported by funding from the Gordon family and the Reagan Corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ayedh K. Alamri, Christy L. Ma, and John J. Ryan declare they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed equally to the conceptualization of this article, review of the literature, writing of this article, and final revision.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}